Major shareholder announcement

GlobeNewswire2021-06-23

Orphazyme A/SCompany announcement No. 18/2021Company Registration No. 32266355 Copenhagen, Denmark, June 23, 2021 – Orphazyme A/S (ORPHA.CO; ORPH) (“the Company”), a late-stage ...

网页链接

免责声明：本文观点仅代表作者个人观点，不构成本平台的投资建议，本平台不对文章信息准确性、完整性和及时性做出任何保证，亦不对因使用或信赖文章信息引发的任何损失承担责任。

精彩评论

chiew
2021-06-24
chiew
70

发表看法

{"i18n":{"language":"zh_CN"},"isChannel":false,"data":{"share":"https://www.laohu8.com/m/news/2145096234?lang=zh_CN&edition=full","thumbnail":"https://s.yimg.com/uu/api/res/1.2/2iUcqQwbjj9QOPtHjGOkfA--~B/aD03NTt3PTM0NTthcHBpZD15dGFjaHlvbg--/https://s.yimg.com/uu/api/res/1.2/vfvfNeFz16X8Xf.Xnz2DtQ--~B/aD03NTt3PTM0NTthcHBpZD15dGFjaHlvbg--/https://media.zenfs.com/en/globenewswire.com/dca640c6ad18044be86fa831a7752766","is_english":true,"pubTime":"2021-06-23 17:43","share_image_url":"https://static.laohu8.com/5f26f4a48f9cb3e29be4d71d3ba8c038","id":"2145096234","market":"us","top_or_hot":-1,"title":"Major shareholder announcement","media":"GlobeNewswire","content":"<div>\n<p>Orphazyme A/SCompany announcement        No. 18/2021Company Registration No. 32266355\nCopenhagen, Denmark, June 23, 2021 – Orphazyme A/S (ORPHA.CO; ORPH) (“the Company”), a late-stage ...</p>\n\n<a href=\"https://finance.yahoo.com/news/major-shareholder-announcement-094300133.html\">网页链接</a>\n\n</div>\n","source":"yahoofinance","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Major shareholder announcement</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nMajor shareholder announcement\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-06-23 17:43 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://finance.yahoo.com/news/major-shareholder-announcement-094300133.html><strong>GlobeNewswire</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Orphazyme A/SCompany announcement        No. 18/2021Company Registration No. 32266355\nCopenhagen, Denmark, June 23, 2021 – Orphazyme A/S (ORPHA.CO; ORPH) (“the Company”), a late-stage ...</p>\n\n<a href=\"https://finance.yahoo.com/news/major-shareholder-announcement-094300133.html\">网页链接</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"GS","symbol_name":"高盛","start_time":0,"source_url":"https://finance.yahoo.com/news/major-shareholder-announcement-094300133.html","article_id":"2145096234","we_media_id":null,"thumbnails":["https://s.yimg.com/uu/api/res/1.2/2iUcqQwbjj9QOPtHjGOkfA--~B/aD03NTt3PTM0NTthcHBpZD15dGFjaHlvbg--/https://s.yimg.com/uu/api/res/1.2/vfvfNeFz16X8Xf.Xnz2DtQ--~B/aD03NTt3PTM0NTthcHBpZD15dGFjaHlvbg--/https://media.zenfs.com/en/globenewswire.com/dca640c6ad18044be86fa831a7752766"],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2145096234","pubTimestamp":1624441380,"sourceInfo":{"source_id":"yahoofinance","name":"雅虎金融"},"weMediaInfo":null,"summary":"Orphazyme A/SCompany announcement        No. 18/2021Company Registration No. 32266355\nCopenhagen, De","collect":0,"end_time":0,"defaultTopTitle":"yahoo.com","property":[],"viewcount":null,"language":"en","relate_stocks":{"GS":"高盛"},"translate_title":"大股东公告","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"ORPH":0.9,"GS":0.89},"content_text":"Orphazyme A/SCompany announcement        No. 18/2021Company Registration No. 32266355\nCopenhagen, Denmark, June 23, 2021 – Orphazyme A/S (ORPHA.CO; ORPH) (“the Company”), a late-stage biopharmaceutical company pioneering the heat shock protein response for the treatment of rare diseases, hereby announces the receipt of notifications pursuant to Section 38 of the Danish Capital Markets Act from The Goldman Sachs Group, Inc., that as of June 16, 2021, The Goldman Sachs Group, Inc.’s aggregate holding of shares and financial instruments increased to 5.58% of the share capital and voting rights in the Company, and as of June 17, 2021, The Goldman Sachs Group, Inc.’s aggregate holding of shares and financial instruments has been reduced to less than 5% of the shares and voting rights in the Company.\nFor additional information, please contact\nOrphazyme A/S\nAnders Vadsholt, CFO                +45 28 98 90 55\nAbout Orphazyme A/SOrphazyme is a late-stage biopharmaceutical company pioneering the heat shock protein response for the treatment of rare diseases. The company is harnessing amplification of heat shock proteins (or HSPs) in order to develop and commercialize novel therapeutics for diseases caused by protein misfolding, protein aggregation, and lysosomal dysfunction. Arimoclomol, the company’s lead candidate, is in clinical development for rare diseases including Niemann-Pick disease type C (NPC) and Gaucher disease. Orphazyme is headquartered in Denmark and has operations in the U.S. and Switzerland. Orphazyme’s shares are listed on Nasdaq U.S. (ORPH) and Nasdaq Copenhagen (ORPHA.CO).\n Attachment \n\n 18-2021 Major shareholder announcement","kind":null,"is_publish_news":false,"is_publish_highlight":false,"is_publish_live":null,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"symbols":[],"gpt_button":1},"commentList":[{"id":128568880,"gmtCreate":1624524123440,"gmtModify":1634004891490,"author":{"id":"3566850909705069","authorId":"3566850909705069","name":"chiew","avatar":"https://static.tigerbbs.com/6a955817d8518ffedcf0489868ef4a98","vip":1,"crmLevel":2,"crmLevelSwitch":0},"htmlText":"70","listText":"70","text":"70","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/128568880","repostId":2145096234,"repostType":2,"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"langContent":"EN"}],"isCommentEnd":false,"newsSizeData":{"likeSize":2,"commentSize":1,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"deviceId":"web-server-community-laohu8-v3","version":"4.25.1","shortVersion":"4.25.1","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2145096234"}